Proton pump inhibitor use and mortality in patients with cirrhosis: a meta-analysis of cohort studies

Xiaoli Wu1, Daofu Zhang2, Yuexiao Yu1, Lianqing Lou1 and Xiaofei Li1

1Department of Infectious Diseases, Yiwu Central Hospital, Yiwu 322000, China; 2Department of Critical Care Medicine, Liaocheng Dongchangfu People’s Hospital, Liaocheng 252000, China

Correspondence: Xiaofei Li (metshep@sina.com)

Background: Proton pump inhibitor (PPI) is commonly used in patients with cirrhosis. However, some studies demonstrated that PPI use was associated with adverse outcome in patients with cirrhosis. We aimed to perform a meta-analysis of cohort studies to evaluate the association between PPI use and mortality in cirrhotic patients.

Methods: Relevant studies were obtained via search of PubMed and Embase databases. A randomized-effect model was used to pool the results. Subgroup analyses were performed to evaluate the source of heterogeneity.

Results: Overall, 21 cohort studies with 20,899 patients and 7457 death events were included. The pooled results with a randomized-effect model showed that PPI use was associated with significantly increased risk of mortality in patients with cirrhosis (adjusted relative risk [RR] = RR: 1.39, P<0.001) with considerable heterogeneity (I²=73%). Subgroup analyses showed that characteristics such as patient ethnicity, sample size, definition of PPI use, and complications of patients did not affect the association. However, the association between PPI use and mortality was independent of study characteristics including patient ethnicity, sample size, complications, definition of PPI use, and follow-up duration. However, the association between PPI use and mortality in cirrhotic patients was significant in retrospective studies (RR: 1.40, P<0.001), but not in prospective studies (RR: 1.34, P=0.33).

Conclusions: PPI use may be associated with moderately increased mortality in cirrhotic patients. Although prospective cohort studies are needed to validate our findings, PPI should only prescribed to cirrhotic patients with indications for the treatment.

Introduction
Proton pump inhibitors (PPIs) are the first-line medications for the treatment of acid-related diseases, such as gastroesophageal reflux disease, peptic ulcer, and Zollinger-Ellison syndrome et al [1–3]. For patients with cirrhosis, PPIs are also commonly used. According to previous data, proportions of cirrhotic patients who were prescribed with PPIs varied from 30% to 80% [4]. However, the indications and clinical efficacy of PPIs in these patients remain to be validated, which highlights the possible overutilization of PPIs in patients with cirrhosis [5]. Subsequently, increasing evidence from epidemiological studies indicated that PPI use may be associated with adverse outcomes in cirrhotic patients, spontaneous bacterial peritonitis (SBP) [6–11], and hepatic encephalopathy (HE) [12,13]. However, it remains unknown whether PPI use affects mortality in these patients. Previous studies evaluating the association between PPI use and mortality risk in patients with cirrhosis showed inconsistent results [14–34]. An early meta-analysis published in 2015 showed that PPI use was not associated with increased mortality in patients with cirrhosis [11]. However, only four cohort studies [14,16,17,19] were included in the present study, and many related cohort studies have been published since the previous meta-analysis [18,20–34]. In addition, it remains unknown
whether study design such as study design, ethnicity of the patients, definition of PPI use, or follow-up duration may affect the outcome. Therefore, we aimed to perform a meta-analysis to systematically evaluate the potential association between PPI use and mortality in patients with cirrhosis.

**Methods**
The meta-analysis was performed in accordance with the MOOSE (Meta-analysis of Observational Studies in Epidemiology) [35] and Cochrane’s Handbook [36] guidelines.

**Literature search**
Studies were identified via systematic search of electronic databases of PubMed and Embase via the following terms: (1) "proton pump inhibitor" OR "proton pump inhibitors" OR "acid suppressive therapy" OR "anti-secretory therapy" OR "PPI" OR "anti-ulcer agent" OR "antacid" OR "omeprazole" OR "esomeprazole" OR "lansoprazole" OR "pantoprazole" OR "rabeprazole" OR "ilaprazole" and (2) "cirrhosis" OR "cirrhotic" OR "liver fibrosis". This extensive search strategy was used to avoid the potential missing of related studies. The search was limited to human studies in English. The reference lists of related original and review articles were also analyzed using a manual approach. The final literature search was performed on September 20, 2019.

**Study selection**
The inclusion criteria for the studies were: (1) cohort studies published in full-length articles in English; (2) included patients with cirrhosis; (3) evaluated the association between PPI use and mortality risk in these patients; and (4) reported the relative risk for the association after adjustment of potential confounding factors. Reviews, editorials, preclinical studies, and studies irrelevant to the aim of current meta-analysis were excluded.

**Data extracting and quality evaluation**
Literature search, data extraction, and quality assessment of the included studies were performed according to the predefined inclusion criteria by two independent authors (X.W. and X.L.). If discrepancies occurred, they were resolved by consensus of the two authors. The extracted data included: (1) name of first author, publication year and country where the study was performed; (2) study design characteristics; (3) ethnicity, characteristics, age, and gender of the participants; (4) definition of PPI use; (5) follow-up durations for cohort studies; and (6) variables that were adjusted when presenting the results. The quality of each study was evaluated using the Newcastle–Ottawa Scale [37] that ranges from 1 to 9 stars and judges each study regarding three aspects: selection of the study groups, the comparability of the groups, and the ascertainment of the outcome of interest.

**Statistical analyses**
We used risk ratios (RRs) and their corresponding 95% confidence intervals (CIs) as the general measure for the association between PPI use and mortality in patients with cirrhosis. Data of RRs and their corresponding standard errors (SEs) were calculated from 95% CIs or P values, and were logarithmically transformed to stabilize variance and normalized the distribution [36]. The Cochrane’s Q test and I² test were used to evaluate the heterogeneity among the include cohort studies [38]. A significant heterogeneity was considered if I² > 50%. We used a randomized-effect model to synthesize the RR data because this model is considered as a more generalized method that incorporates of the potential heterogeneity [36]. Sensitivity analyses, by removing individual study one at a time, were performed to test the robustness of the results [39]. Predefined subgroup analyses were performed to evaluate the influences of study characteristics on the outcome, including study design, patient ethnicity, patient characteristics, sample size, definition of PPI use, and follow-up durations. The potential publication bias was assessed by funnel plots with the Egger regression asymmetry test [40]. We used the RevMan (Version 5.1; Cochrane Collaboration, Oxford, U.K.) and STATA software for the meta-analysis and statistics.

**Results**

**Literature search**
The process of database search is summarized in Figure 1. Briefly, 1312 articles were found via initial literature search of the PubMed and Embase databases, and 1264 were excluded through screening of the titles and abstracts mainly because they were not relevant to the purpose of the meta-analysis. Subsequently, 48 potential relevant records underwent full-text review. Of these, 27 were further excluded because two of them did not include patients with cirrhosis,
Figure 1. Flowchart of database search and study identification

one did not analyze PPI in cirrhotic patients, 15 did not report mortality outcome, two did not provide adjusted data for the association, and the other seven were abstracts of the already included studies. Finally, 21 cohort studies were included [14–34].

Study characteristics and quality evaluation
The characteristics of the included studies are summarized in Table 1. Overall, 21 cohort studies with 20,899 patients and 7457 death events were included, of which 16 were retrospective cohort studies [16–19,22–33], while the other five were prospective cohort [14,15,20,21,34]. As for the ethnicity of the patients, 12 studies included Caucasian patients [15,16,18,20–22,24,28,29,32–34], 7 included Asians [17,19,23,25,26,30,31], and the remaining 2 included patients with mixed ethnicity [14,27]. Most of the studies included patients with hospitalized patients with cirrhosis without serious clinical complications [14–18,20–24,28–30,32,34], while six studies included cirrhotic patients with SBP [19,26], HE [25], Clostridium difficile infection [27], pneumonia [31], and after transjugular intrahepatic portosystemic shunt [33], respectively. The mean ages of the patients varied from 53 to 63 years, and the proportions
| Study                  | Country        | Design | Ethnicity | Patient characteristics | Sample size | Mean age (Years) | Male % | Definitions of PPI use                        | Follow-up durations (Months) | Death (n) | Variables adjusted                                                                 |
|-----------------------|----------------|--------|-----------|--------------------------|-------------|------------------|--------|-----------------------------------------------|-------------------------------|------------|-------------------------------------------------------------------------------------|
| van Vlerken 2012      | The Netherlands| PC     | Caucasian | Cirrhotic patients with ascites | 84          | 55.0             | 67.0   | Any PPI use within follow-up                 | 28                            | 17         | Age, gender, and Child-Pugh class                                                   |
| Bajaj 2012            | US             | PC     | Mixed     | Cirrhotic patients        | 207         | 55.0             | 59.9   | Current PPI use at admission                | 1                             | 49         | Age, gender, MELD score, albumin, serum sodium, SOFA score                         |
| de Vos 2013           | Belgium        | RC     | Caucasian | Cirrhotic patients with ascites | 51          | 57.5             | 68.6   | Current use for at least 2 weeks by medical record review | 12                            | 40         | Age, gender, INR, MELD score, and Child-Pugh class                                |
| Min 2014              | Korea          | RC     | Asian     | Cirrhotic patients with SBP | 134         | 58               | 73.9   | Any PPI use during hospitalization          | Within hospitalization        | 41         | Age, gender, serum sodium, MELD score, and Child-Pugh class                        |
| Kwon 2014             | Korea          | RC     | Asian     | Cirrhotic patients with ascites | 533         | 62.3             | 75.4   | Current use of PPI within 30 days before admission | 1                            | 175        | Age, gender, and MELD score                                                        |
| Mandorfer 2014        | Austria        | RC     | Caucasian | Cirrhotic patients with ascites | 607         | 57.5             | 70.0   | Current use on admission by medical record review | 10                            | 358        | Age, gender, and MELD score                                                        |
| Dultz 2015            | Germany        | PC     | Caucasian | Cirrhotic patients        | 272         | 57.0             | 66.9   | Current PPI use at admission                | 9                             | 86         | Age, gender, etiology of cirrhosis, and MELD Score                                  |
| Merli 2015            | Italy          | PC     | Caucasian | Cirrhotic patients        | 400         | 61.5             | 70.3   | Any PPI use during hospitalization          | Within hospitalization        | 39         | Age, gender, and MELD score                                                        |
| Cole 2016             | U.K.           | RC     | Caucasian | Cirrhotic patients        | 198         | 56.0             | 65.2   | Current PPI use at discharge                | 23                            | 38         | Age, gender, and MELD score                                                        |
| Kim 2017              | Korea          | RC     | Asian     | Cirrhotic patients with a previous SBP | 307         | 57.6             | 77.1   | Any PPI use for at least 1 week during follow-up | Within hospitalization        | 91         | Age, gender, etiology of liver disease, serum sodium, SCr, and Child-Pugh class   |
| Miozzo 2017           | Brazil         | RC     | Caucasian | Cirrhotic patients        | 258         | 53.6             | 58.2   | Any PPI use during follow-up                | 30                            | 155        | Age, gender, and MELD score                                                        |
| Hung 2018a            | China          | RC     | Asian     | Cirrhotic patients with SBP | 2574        | 60.9             | 71.8   | Current PPI use during hospitalization      | 12                            | 1785       | Age, gender, and MELD score                                                        |
| Hung 2018b            | China          | RC     | Asian     | Cirrhotic patients with HE | 5020        | 62.5             | 68.0   | Current PPI use during hospitalization      | 12                            | 3210       | Age, gender, etiology of cirrhosis, and MELD score                                  |
| Smith 2018            | US             | RC     | Mixed     | Cirrhotic patients with CDI | 400         | 58.5             | 60.0   | Current PPI use at admission                | 30                            | 44         | Age, gender, serum albumin, and MELD score                                         |
| Tergast 2018          | Germany        | RC     | Caucasian | Cirrhotic patients with ascites | 613         | 56.1             | 62.0   | Current PPI use within 7 days before admission | 1                             | 121        | Age, gender, and MELD score                                                        |
| Janka 2019            | Hungary        | RC     | Caucasian | Cirrhotic patients        | 350         | 56.0             | 53.7   | Regular use of PPI for at least 80% of follow-up periods based on medical chart review | 60                            | 147        | Age, gender, and MELD score                                                        |
| Nardelli 2019         | Italy          | PC     | Caucasian | Cirrhotic patients        | 310         | 62.2             | 71.3   | Current PPI use at least 4 weeks before admission | 14                            | 112        | Age, gender, serum albumin, serum sodium, and MELD score                          |
| Lewis 2019            | US             | RC     | Caucasian | Cirrhotic patients after TIPS | 2284        | 56.4             | 66.1   | Any PPI use at follow-up                    | 13                            | 115        | Age, gender, and MELD score                                                        |

Continued over
| Study   | Country | Design | Ethnicity | Patient characteristics | Sample size | Mean age Years | Male % | Definitions of PPI use                                      | Follow-up durations Months | Death (n) | Variables adjusted                                                                 | NOS |
|---------|---------|--------|-----------|--------------------------|-------------|----------------|--------|-------------------------------------------------------------|----------------------------|-----------|-------------------------------------------------------------------------------------|-----|
| Dam 2019 | Denmark  | RC     | Caucasian | Cirrhotic patients       | 1198        | 57.5           | 70.0   | Current PPI use at admission                               | 3                           | 81        | Age, gender, MELD score, history of variceal bleeding, and history of HE            | 7   |
| Hung 2019 | China    | RC     | Asian     | Cirrhotic patients with pneumonia | 4804        | 63.0           | 71.2   | Current PPI use during hospitalization                     | 3                           | 638       | Age, gender, etiology of cirrhosis, and MELD score                                  | 7   |
| De Roza 2019 | Singapore | RC     | Asian     | Cirrhotic patients       | 295         | 62.8           | 68.1   | Any PPI use at follow-up                                  | 6                           | 115       | Age, gender, etiology of cirrhosis, history of variceal bleeding and HE, and MELD score | 8   |

Abbreviations: CDI, *Clostridium difficile* infection; DM, diabetes mellitus; HE, hepatic encephalopathy; INR, international normalized ratio; MELD, Model for End-stage Liver Disease; NOS, the Newcastle–Ottawa Score; PC, prospective cohort; PPI, proton pump inhibitor; RC, retrospective cohort; SCr, serum creatinine; SBP, spontaneous bacterial peritonitis; TIPS, transjugular intrahepatic portosystemic shunt.
Table 2 Details of study quality evaluation by the Newcastle–Ottawa Scale

| Study          | Representativeness | Selection of the exposed cohort | Selection of the non-exposed cohort | Ascertainment of exposure | Outcome not present at baseline | Control for age and gender | Control for other confounding factors | Assessment of outcome | Enough long follow-up duration | Adequacy of follow-up of cohorts | Total |
|----------------|--------------------|---------------------------------|--------------------------------------|---------------------------|---------------------------------|-----------------------------|--------------------------------------|----------------------|-----------------------------|----------------------------------|-------|
| van Vlerken 2012 | 0                  | 1                               | 0                                    | 1                         | 1                               | 1                           | 1                                    | 1                    | 1                           | 1                                | 7     |
| Bajaj 2012      | 1                  | 1                               | 0                                    | 1                         | 1                               | 1                           | 1                                    | 1                    | 1                           | 1                                | 8     |
| de Vos 2013     | 0                  | 1                               | 1                                    | 1                         | 1                               | 1                           | 0                                    | 1                    | 1                           | 1                                | 8     |
| Min 2014        | 0                  | 1                               | 1                                    | 1                         | 1                               | 1                           | 0                                    | 1                    | 1                           | 1                                | 8     |
| Kwon 2014       | 1                  | 1                               | 0                                    | 1                         | 1                               | 1                           | 1                                    | 1                    | 1                           | 1                                | 8     |
| Mandorfer 2014  | 1                  | 1                               | 1                                    | 1                         | 1                               | 1                           | 1                                    | 1                    | 1                           | 0                                | 8     |
| Dultz 2015      | 1                  | 1                               | 0                                    | 1                         | 1                               | 1                           | 1                                    | 1                    | 1                           | 1                                | 8     |
| Merli 2015      | 1                  | 1                               | 1                                    | 1                         | 1                               | 1                           | 0                                    | 0                    | 1                           | 1                                | 7     |
| Cole 2016       | 0                  | 1                               | 0                                    | 1                         | 1                               | 1                           | 1                                    | 1                    | 1                           | 1                                | 7     |
| Kim 2017        | 1                  | 0                               | 0                                    | 1                         | 1                               | 1                           | 1                                    | 1                    | 1                           | 1                                | 7     |
| Miozzo 2017     | 0                  | 1                               | 0                                    | 1                         | 1                               | 1                           | 1                                    | 1                    | 1                           | 1                                | 7     |
| Hung 2018a      | 1                  | 0                               | 0                                    | 1                         | 1                               | 1                           | 1                                    | 1                    | 1                           | 1                                | 7     |
| Hung 2018b      | 1                  | 0                               | 0                                    | 1                         | 1                               | 1                           | 1                                    | 1                    | 1                           | 1                                | 7     |
| Smith 2018      | 0                  | 1                               | 0                                    | 1                         | 1                               | 1                           | 1                                    | 1                    | 1                           | 1                                | 7     |
| Tergast 2018    | 1                  | 1                               | 1                                    | 1                         | 1                               | 1                           | 0                                    | 1                    | 1                           | 1                                | 8     |
| Janka 2019      | 0                  | 1                               | 1                                    | 0                         | 1                               | 1                           | 1                                    | 1                    | 1                           | 1                                | 7     |
| Nardelli 2019   | 1                  | 1                               | 1                                    | 1                         | 1                               | 1                           | 1                                    | 1                    | 1                           | 1                                | 9     |
| Lewis 2019      | 0                  | 1                               | 1                                    | 1                         | 1                               | 1                           | 1                                    | 1                    | 1                           | 1                                | 8     |
| Dam 2019        | 1                  | 1                               | 0                                    | 1                         | 1                               | 1                           | 1                                    | 0                    | 1                           | 1                                | 7     |
| Hung 2019       | 1                  | 0                               | 0                                    | 1                         | 1                               | 1                           | 1                                    | 1                    | 1                           | 1                                | 7     |
| De Roza 2019    | 1                  | 1                               | 1                                    | 1                         | 1                               | 1                           | 1                                    | 1                    | 0                           | 1                                | 8     |

of male patients varied from 53% to 77%. PPI use was defined as concurrent use at the admission in 13 studies [14,16–18,20,22,25–29,31,34], and any use during follow up in eight studies [15,19,21,23,24,30,32,33]. The follow-up durations varied from within hospitalization to 60 months. Variables including age, gender, comorbidities, and scale for disease severity, such as the Child-Pugh class or the Model for End-stage liver Disease (MELD) score were adjusted when presenting the association between PPI use and mortality. The qualities of the included cohorts were generally good, with NOS scores ranging between 7 and 9 (Table 2).

Association between PPI use and mortality in patients with cirrhosis

Meta-analysis with a randomized-effect model including 21 studies showed that use of PPI was significantly associated with mortality in cirrhotic patients (RR: 1.39, 95% CI: 1.19–1.62, P <0.001; Figure 2) with significant heterogeneity (P for Cochrane’s Q test < 0.001, I² = 73%). Results of sensitivity analyses by omitting one dataset at a time did not significantly change the results (RR: 1.31–1.43, P all < 0.001; Table 3). Subgroup analyses according to the study design showed that the association between PPI use and mortality risk in patients with cirrhosis was significant in retrospective cohort studies (16 studies, RR: 1.40, 95% CI: 1.20–1.64, P <0.001), but not in prospective cohort studies (five studies, RR: 1.34, 95% CI: 0.75–2.40, P = 0.33; Table 4). However, the difference between the subgroups was not significant (P = 0.88). The association between PPI use and mortality in cirrhotic patients was significant and not affected by study characteristics including patient ethnicity, with or without severe complications, sample size, definition of PPI use, or follow-up durations (Table 4).

Publication bias

The funnel plots regarding the association between PPI use and mortality in cirrhotic patients were shown in Figure 3. The funnel plots were symmetry on visual inspection, suggesting low chance of significant publication bias. Results of Egger’s regression test also suggested that no significant publication bias (P = 0.65).
Figure 2. Forest plots for the meta-analysis of the association between PPI use and mortality in cirrhotic patients

Table 3 Results of sensitivity analysis

| Studies omitted | RR   | 95% CI    | I²  | P for effect |
|-----------------|------|-----------|-----|--------------|
| van Vlerken 2012 | 1.37 | 1.18-1.60 | 74% | <0.001       |
| Bajaj 2012      | 1.42 | 1.21-1.66 | 73% | <0.001       |
| de Vos 2013     | 1.41 | 1.20-1.66 | 74% | <0.001       |
| Min 2014        | 1.38 | 1.18-1.62 | 74% | <0.001       |
| Kwon 2014       | 1.37 | 1.17-1.60 | 73% | <0.001       |
| Mandorfer 2014  | 1.42 | 1.21-1.67 | 73% | <0.001       |
| Dultz 2015      | 1.36 | 1.17-1.59 | 73% | <0.001       |
| Merli 2015      | 1.43 | 1.23-1.67 | 71% | <0.001       |
| Cole 2016       | 1.39 | 1.19-1.63 | 74% | <0.001       |
| Kim 2017        | 1.38 | 1.18-1.62 | 74% | <0.001       |
| Miozzo 2017     | 1.43 | 1.22-1.67 | 70% | <0.001       |
| Hung 2018a      | 1.40 | 1.18-1.67 | 74% | <0.001       |
| Hung 2018b      | 1.41 | 1.19-1.68 | 74% | <0.001       |
| Smith 2018      | 1.38 | 1.18-1.62 | 74% | <0.001       |
| Tergast 2018    | 1.37 | 1.17-1.60 | 74% | <0.001       |
| Janka 2019      | 1.36 | 1.16-1.59 | 72% | <0.001       |
| Nardelli 2019   | 1.37 | 1.17-1.60 | 73% | <0.001       |
| Lewis 2019      | 1.31 | 1.14-1.50 | 62% | <0.001       |
| Dam 2019        | 1.42 | 1.22-1.67 | 73% | <0.001       |
| Hung 2019       | 1.40 | 1.19-1.67 | 74% | <0.001       |
| De Roza 2019    | 1.36 | 1.17-1.59 | 73% | <0.001       |

Abbreviations: CI, confidence interval; RR, risk ratio.

© 2020 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY).
Table 4 Subgroup analyses for the meta-analysis of the association between PPI use and mortality in patients with cirrhosis

| Characteristics                        | Dataset number | RR (95% CI)            | P for subgroup effect | P for subgroup difference |
|----------------------------------------|----------------|------------------------|-----------------------|---------------------------|
| Study design                           |                |                        |                       |                           |
| PC                                     | 5              | 1.34 [0.75, 2.40]      | 0.33                  | 79%                       |
| RC                                     | 16             | 1.40 [1.20, 1.64]      | <0.001                | 73%                       |
| Ethnicity                              |                |                        |                       |                           |
| Caucasian                              | 12             | 1.42 [1.07, 1.90]      | 0.02                  | 83%                       |
| Asian                                  | 7              | 1.32 [1.18, 1.48]      | <0.001                | 17%                       |
| Patient characteristics                |                |                        |                       |                           |
| With complications or after procedure  |                |                        |                       |                           |
| Caucasian                              | 6              | 1.50 [1.19, 1.89]      | 0.001                 | 79%                       |
| Asian                                  | 15             | 1.34 [1.08, 1.67]      | 0.008                 | 71%                       |
| Without complications                  |                |                        |                       |                           |
| Number of participants                 |                |                        |                       |                           |
| >500                                   | 11             | 1.33 [1.03, 1.72]      | 0.03                  | 71%                       |
| ≤500                                   | 10             | 1.45 [1.18, 1.78]      | 0.004                 | 76%                       |
| Definition of PPI use                  |                |                        |                       |                           |
| Current PPI use at admission           |                |                        |                       |                           |
| >500                                   | 13             | 1.28 [1.13, 1.46]      | <0.001                | 48%                       |
| Any PPI use during follow-up           |                |                        |                       |                           |
| ≤1 month                               | 9              | 1.19 [1.01, 1.40]      | 0.04                  | 70%                       |
| >1 month                               | 15             | 1.42 [1.20, 1.68]      | <0.001                | 76%                       |
| Follow-up durations                    |                |                        |                       |                           |
| ≤1 month                               | 9              | 1.19 [1.01, 1.40]      | 0.04                  | 70%                       |
| >1 month                               | 15             | 1.42 [1.20, 1.68]      | <0.001                | 76%                       |

Abbreviations: CI, confidence interval; PPI, proton pump inhibitor; PR, prospective cohort; RC, retrospective cohort; RR, risk ratio.

Figure 3. Funnel plots for the meta-analysis of the association between PPI use and mortality in cirrhotic patients

© 2020 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY).
Discussion

Results of this meta-analysis showed that PPI use was associated with moderately increased mortality in patients with cirrhosis. The association between PPI use and mortality in cirrhotic patients seemed to be independent of demographic factors and scales indicating the disease severity because we included data after adjustment of these confounding factors. Moreover, sensitivity analyses by omitting one study at a time indicated the robustness of the outcome. Subgroup analyses also suggested that the association between PPI use and mortality in cirrhotic patients was consistent in different subgroups according to study characteristics including patient ethnicity, sample size, with or without patient complications, definition of PPI use, and follow-up durations. Although the association between PPI use and mortality was significant in subgroup of retrospective studies but not in subgroups of prospective studies, the difference between the subgroups was not significant. Taken together, these results indicated that PPI use may be associated with increased mortality risk in patients with cirrhosis. Although these findings should be validated in large-scale prospective studies, considering the potential overutilization of PPI in cirrhotic patients, carefully selection of cirrhotic patients with appropriate indications for PPI therapy is recommended before using the medication.

An early meta-analysis published in 2016 failed to show a significant association between PPI use and mortality risk in cirrhotic patients [11]. As mentioned by the authors, the limited number of available studies and sample size may lead to statistical inadequacy of the meta-analysis to reach a positive outcome. Our meta-analysis, by including 21 available cohort studies with 20,899 patients, showed that PPI use was associated with increased mortality in cirrhotic patients. Despite of the large number of studies included, our study has the following strengths. First, we only included article published in peer-reviewed journal, which therefore is of low risk of selection bias. Second, RRs data after adjustment of multiple confounding factors were included and combined, which therefore provide an independent association between PPI use and mortality risk in cirrhosis patients. Third, we performed exhausting sensitivity and subgroup analyses to evaluate the potential influence of individual study and study characteristics on the outcome. These studies confirmed the robustness of the meta-analysis result, which was not likely to be driven by a single study or affected by study characteristics including patient ethnicity, sample size, with or without complications, definition of PPI, and follow-up durations. Although we found that the association between PPI use and mortality risk was significant in retrospective studies but not in prospective studies, difference between the subgroups was not statistically. Moreover, only five prospective cohorts were available. Therefore, it was likely that the non-significant association between PPI use and mortality risk in subgroup of prospective cohorts may probably be attributed to limited studies available. Since retrospective cohort studies is exposed to recall bias [41], large-scale prospective cohort studies are needed to validate our findings. Collectively, results of this meta-analysis support that PPI is associated with increased mortality in cirrhotic patients. Considering the potential overutilization of PPIs in patients with cirrhosis [5], as well as the potential safety consideration related to the long-term use of PPIs [3], decision for the prescription of PPIs in cirrhotic patients should only be made after carefully evaluating the appropriate indications and balancing the benefits and potential risk of adverse outcomes in these patients.

The reasons and mechanisms for the increased mortality risk associated with PPI use in cirrhotic patients may be multifactorial. First, PPIs, by suppressing gastric acids, may cause bacterial overgrowth in both stomach and intestine [42,43]. Subsequently, the impaired intestinal epithelial barrier in patients with cirrhosis [44] may facilitate the translocation of the overgrown bacteria to mesenteric lymph nodes, which finally leads to SBP and other infections [45]. Moreover, PPIs may also contribute to the gut dysbiosis that generally exists in patients with cirrhosis, whereas altered gut microbiota can induce or exacerbate HE [46,47], another complication that has been related to increased mortality risk in cirrhotic patients [12]. In addition, studies in overall population showed that PPI use may be associated with increased risks of cardiovascular adverse events [48], stroke [49], and fractures [50], which may also lead to increased mortality. Studies regarding the safety of PPI use in various populations, particularly the long-term use of PPI, should be performed to confirm these mechanisms.

Our study has limitations which should be considered when interpreting the results. First, significant heterogeneity exists among the included studies. Although exploring subgroup analyses were performed to evaluate the potential source of heterogeneity, the results of subgroup analyses should be interpreted with caution since the numbers of available studies were limited for each stratum of subgroups. Moreover, since the individual patient data were not available, we could only perform subgroup analyses based on study-level data. The influences of patient and study characteristics on the association between PPI use and mortality in cirrhotic patients should be further analyzed in future studies. Second, although we included studies with adjusted data for the association between PPI use and mortality, we could not exclude the existence of residual factors which may confound the association. Third, a causative association between PPI use and mortality in cirrhotic patients should not be derived based on our finding since the present study was a meta-analysis of observational studies. Randomized controlled trials should be considered to
validate the influence of PPI on clinical outcomes in cirrhosis patients. Finally, we could not determine whether the dosages, durations, or individual PPI medications may affect the clinical outcomes of cirrhotic patients differently. Future studies are also warranted in this regard.

**Conclusions**

In conclusion, results of our meta-analysis indicated that PPI use may be associated with increased mortality risk in cirrhotic patients. Although these findings should be validated in large-scale prospective studies, considering the potential overutilization of PPI in cirrhotic patients, carefully selection of cirrhotic patients with appropriate indications for PPI therapy is recommended before using the medication.

**Competing Interests**

The authors declare that there are no competing interests associated with the manuscript.

**Funding**

The authors declare that there are no sources of funding to be acknowledged.

**Author Contribution**

X.W. and X.L. conceived and designed the study. X.W. and D.Z. selected the studies and collected the data. X.W., D.Z., Y.Y., and L.L. analyzed data, and all authors interpreted the results. X.W and X.L drafted and revised the paper. All authors revised the draft paper. All authors read and approved the final version of the manuscript.

**Abbreviations**

CDI, *Clostridium difficile* Infection; DM, diabetes mellitus; HE, hepatic encephalopathy; INR, international normalized ratio; MELD, Model for End-stage liver Disease; NOS, the Newcastle–Ottawa Score; PC, prospective cohort; PPI, proton pump inhibitor; RC, retrospective cohort; SBP, spontaneous bacterial peritonitis; SCr, serum creatinine; TIPS, transjugular intrahepatic portosystemic shunt.

**References**

1. Vaezi, M.F., Yang, X.Y. and Howden, C.W. (2017) Complications of Proton Pump Inhibitor Therapy. *Gastroenterology* **153**, 35–48, https://doi.org/10.1016/j.gastro.2017.04.047
2. Weersink, R.A., Bouma, M., Burger, D.M. et al. (2018) Safe use of proton pump inhibitors in patients with cirrhosis. *Br. J. Clin. Pharmacol.* **84**, 1806–1820, https://doi.org/10.1111/bcp.13615
3. Corley, D.A. (2019) Safety and Complications of Long-Term Proton Pump Inhibitor Therapy: Getting Closer to the Truth. *Gastroenterology* **157**, 604–607, https://doi.org/10.1053/j.gastro.2019.07.039
4. Chavez-Tapia, N.C., Tellez-Avila, F.I., Garcia-Leiva, J. and Valdovinos, M.A. (2008) Use and overuse of proton pump inhibitors in cirrhotic patients. *Med. Sci. Monit.* **14**, CR468–CR472
5. Heidelbaugh, J.J., Kim, A.H., Chang, R. and Walker, P.C. (2012) Overutilization of proton-pump inhibitors: what the clinician needs to know. *Therap. Adv. Gastroenterol.* **5**, 219–232, https://doi.org/10.1177/1756283X12437358
6. Trikudanathan, G., Israel, J., Cappa, J. and O’Sullivan, D.M. (2011) Association between proton pump inhibitors and spontaneous bacterial peritonitis in cirrhotic patients - a systematic review and meta-analysis. *Int. J. Clin. Pract.* **65**, 674–678, https://doi.org/10.1111/i1742-1241.2011.02650.x
7. Siple, J.F., Morey, J.M., Gutman, T.E., Weinberg, K.L. and Collins, P.D. (2012) Proton pump inhibitor use and association with spontaneous bacterial peritonitis in patients with cirrhosis and ascites. *Ann. Pharmacother.* **46**, 1413–1418, https://doi.org/10.1345/aph.1r174
8. Deshpande, A., Pasupuleti, V., Thota, P. et al. (2013) Acid-suppressive therapy is associated with spontaneous bacterial peritonitis in cirrhotic patients: a meta-analysis. *J. Gastroenterol. Hepatol.* **28**, 235–242, https://doi.org/10.1111/j.1440-1746.2012.06837.x
9. Khan, M.A., Kamal, S., Khan, S., Lee, W.M. and Howden, C.W. (2015) Systematic review and meta-analysis of the possible association between pharmacological gastric acid suppression and spontaneous bacterial peritonitis. *Eur. J. Gastroenterol. Hepatol.* **27**, 1327–1336, https://doi.org/10.1097/MEG.000000000000448
10. Xu, H.B., Wang, H.D., Li, C.H. et al. (2015) Proton pump inhibitor use and risk of spontaneous bacterial peritonitis in cirrhotic patients: a systematic review and meta-analysis. *Genet. Mol. Res.* **14**, 7490–7501, https://doi.org/10.4238/2015.July.3.25
11. Yu, T., Tang, Y., Jiang, L., Zheng, Y., Xiong, W. and Lin, L. (2016) Proton pump inhibitor therapy and its association with spontaneous bacterial peritonitis incidence and mortality: A meta-analysis. *Dig. Liver Dis.* **48**, 353–359, https://doi.org/10.1016/j.dld.2015.12.009
12. Ma, Y.J., Cao, Z.X., Li, Y. and Feng, S.Y. (2019) Proton pump inhibitor use increases hepatic encephalopathy risk: A systematic review and meta-analysis. *World J. Gastroenterol.* **25**, 2675–2682, https://doi.org/10.3748/wjg.v25.i21.2675
13. Tantali, X.X., Yang, L.B., Wei, Z.C. et al. (2019) Association of proton pump inhibitors with risk of hepatic encephalopathy in advanced liver disease: A meta-analysis. *World J. Gastroenterol.* **25**, 2683–2698, https://doi.org/10.3748/wjg.v25.i21.2683
14. Bajaj, J.S., O’Leary, J.G., Reddy, K.R. et al. (2012) Second infections independently increase mortality in hospitalized patients with cirrhosis: the North American consortium for the study of end-stage liver disease (NACSELD) experience. *Hepatology* **56**, 2328–2335, https://doi.org/10.1002/hep.25947
44 Pijls, K.E., Jonkers, D.M., Elamin, E.E., Mascele, A.A. and Koek, G.H. (2013) Intestinal epithelial barrier function in liver cirrhosis: an extensive review of the literature. *Liver Int.* **33**, 1457–1469

45 Runyon, B.A., Squier, S. and Borzio, M. (1994) Translocation of gut bacteria in rats with cirrhosis to mesenteric lymph nodes partially explains the pathogenesis of spontaneous bacterial peritonitis. *J. Hepatol.* **21**, 792–796, https://doi.org/10.1016/S0168-8278(94)80241-6

46 Bajaj, J.S., Cox, I.J., Betrapally, N.S. et al. (2014) Systems biology analysis of omeprazole therapy in cirrhosis demonstrates significant shifts in gut microbiota composition and function. *Am. J. Physiol. Gastrointest. Liver Physiol.* **307**, G951–G957, https://doi.org/10.1152/ajpgi.00268.2014

47 Gupta, A., Dhiman, R.K., Kumari, S. et al. (2010) Role of small intestinal bacterial overgrowth and delayed gastrointestinal transit time in cirrhotic patients with minimal hepatic encephalopathy. *J. Hepatol.* **53**, 849–855, https://doi.org/10.1016/j.jhep.2010.05.017

48 Hu, W., Tong, J., Kuang, X., Chen, W. and Liu, Z. (2018) Influence of proton pump inhibitors on clinical outcomes in coronary heart disease patients receiving aspirin and clopidogrel: A meta-analysis. *Medicine (Baltimore).* **97**, e9638, https://doi.org/10.1097/MD.0000000000009638

49 Malhotra, K., Katsanos, A.H., Bilal, M., Ishfaq, N. and Tsivgoulis, G. (2018) Cerebrovascular Outcomes With Proton Pump Inhibitors and Thienopyridines: A Systematic Review and Meta-Analysis. *Stroke* **49**, 312–318, https://doi.org/10.1161/STROKEAHA.117.019166

50 Poly, T.N., Islam, M.M., Yang, H.C., Wu, C.C. and Li, Y.J. (2019) Proton pump inhibitors and risk of hip fracture: a meta-analysis of observational studies. *Osteoporos. Int.* **30**, 103–114, https://doi.org/10.1007/s00198-018-4788-y